Compounded Bioidentical Menopausal Hormone Therapy
Publication Date: October 31, 2023
Last Updated: January 19, 2024
Summary of Consensus Recommendations
Safety and Efficacy of Custom-Compounded Hormone Therapy
There is a lack of high-quality data on the safety and efficacy of custom-compounded bioidentical hormone therapy for the management of menopausal symptoms. Compounded bioidentical menopausal hormone therapy should not be prescribed routinely when FDA-approved formulations exist.
6731
There is no FDA-approved testosterone formulation for the management of menopausal symptoms. Clinicians and patients should use a shared decision-making framework when considering the use of compounded testosterone for this indication. Based on the lack of safety data and inability to remove the pellet, ACOG recommends preparations other than pellet therapy for the delivery of testosterone.
6731
Title
Compounded Bioidentical Menopausal Hormone Therapy
Authoring Organization
American College of Obstetricians and Gynecologists